Evidence map›Paper›PMID 37417558›Full record

ArticleInvestigative and clinical urology2023

Comparative analysis of mortality and progression to end-stage renal disease between surgically induced and medical chronic kidney disease: A study using the National Health Insurance customized database.

Gyoohwan Jung, Seokwoo Park, Hasung Kim, Jungkuk Lee, Chang Wook Jeong

Open access · diamondAbstract read
In one paragraph

Article in Investigative and clinical urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Gyoohwan JungDepartment of Urology, Hanyang University Seoul Hospital, Seoul, Korea.ORCID 0000-0002-1602-0036
Seokwoo ParkDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.ORCID 0000-0003-2758-1362
Hasung KimData Science Team, Hanmi Pharm. Co., Ltd, Seoul, Korea.ORCID 0000-0002-2519-6244
Jungkuk LeeData Science Team, Hanmi Pharm. Co., Ltd, Seoul, Korea.ORCID 0000-0003-1874-449X
Chang Wook JeongDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-2200-5019
Hanmi Pharmaceutical (South Korea) · KRHanyang University Seoul Hospital · KRSeoul National University · KRSeoul National University Bundang Hospital · KR

Funding

Korean Urological Association 2021-KUA-004
6 · The paper itself

Abstract

purposeWe aimed to compare the mortality rate and the risk for progression to end-stage renal disease (ESRD) and cardiovascular disease (CVD) between patients who underwent surgery for localized renal cell carcinoma (RCC) and those with chronic kidney disease (CKD) without surgery by investigating the National Health Insurance Service. MATERIALS AND

methodsThe surgical group (CKD-S) included patients who underwent radical or partial nephrectomy for RCC from 2007 to 2009. Grades of surgical CKD were classified according to the estimated glomerular filtration rate (eGFR) measured at a health screening within 2 years after surgery. The nonsurgical group (CKD-M) was graded according to the eGFR in the 2009-2010 health screenings. We performed 1:5 propensity score matching for age, gender, diabetes, hypertension, Charlson comorbidity index, smoking, alcohol consumption, baseline eGFR, and body mass index.

resultsA total of 8,698 patients (CKD-S, n=1,521; CKD-M, n=7,177) were analyzed. The CKD-M group was at higher risk for progression to ESRD (hazard ratio [HR] 1.90, 95% confidence interval [CI] 1.04-3.44, p=0.036) and CVD (HR 1.17, 95% CI 1.06-1.29, p=0.002) than the CKD-S group. In the group of patients with grade 3 disease or higher, the CKD-M group was at significantly higher risk for progression to ESRD (HR 2.21, 95% CI 1.47-3.31, p<0.001), CVD (HR 1.32, 95% CI 1.20-1.45, p<0.001), and overall mortality (HR 1.50, 95% CI 1.21-1.86, p<0.001).

conclusionsThe risk for progression to ESRD, CVD, or mortality in patients with CKD-S may be lower than in patients with CKD-M.

Indexed as

Carcinoma, Renal CellCardiovascular DiseasesKidney Failure, ChronicKidney NeoplasmsRenal Insufficiency, ChronicHumansRisk FactorsCardiovascular diseasesChronic kidney diseaseKidney failureSurgical procedures, operativeSurvival

Identifiers

PMID37417558
PMCPMC10330416
OpenAlexW4380685713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.